Effects of ZA and IL-2 on γ9δ2 T cells
Patients treated with zolbetuximab + ZA + intermediate-dose IL-2 (Arm 3) experienced expansion of γ9δ2 T cells by Day 8. A fivefold increase in median γ9δ2 T-cell frequency was observed by Day 8, compared with pretreatment levels (Fig. Kinetic profile of γ9δ2 T-cell frequency in lymphocytes. Kinetic profile of γ9δ2 T-cell frequency in lymphocytes. Peripheral blood mononuclear cells from patients were analyzed by flow cytometry at nine different time points (D1, D3, D8, D22, D43, D45, D50, D64, and D85). Frequencies of activated CD69Kinetic profile of activated CD69